Roivant Sciences (ROIV) Cash from Financing Activities (2020 - 2026)

Roivant Sciences (ROIV) has 6 years of Cash from Financing Activities data on file, last reported at $203.0 million in Q4 2025.

• Quarterly Cash from Financing Activities rose 119.47% year-over-year to $203.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$964.8 million (up 29.08% YoY) and the FY2026 annual result came in at $134.2 million, up 111.0% from the prior year.
• Cash from Financing Activities advanced to $203.0 million in Q4 2025, from $62.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $452.0 million in Q4 2023 to a low of -$1.0 billion in Q4 2024.
• A 5-year average of -$1.6 million and a median of $62.6 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 2931.66% — and 2024, when it plunged 8935.31%.
• Tracing ROIV's Cash from Financing Activities over 5 years: stood at $305.7 million in 2021, then declined by 5.43% to $289.1 million in 2022, then soared by 56.33% to $452.0 million in 2023, then plunged by 330.68% to -$1.0 billion in 2024, then soared by 119.47% to $203.0 million in 2025.
• The last three Cash from Financing Activities figures came in at $203.0 million (Q4 2025), $62.6 million (Q3 2025), and -$187.8 million (Q2 2025), per Business Quant data.